Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.
European Society for Medical Oncology (ESMO)
First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.
Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
A suite of assays that rely on a single instrument and its related software could help researchers identify factors that drive immunotherapy response.
Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Cabozantinib Effective Regardless of PD-L1 Expression in RCC
PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.
Larotrectinib Continues to Show Efficacy in TRK-Fusion Cancers
The TRK inhibitor larotrectinib continues to show efficacy in TRK-fusion cancers, regardless of patient age or cancer type.
First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.
Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
Talazoparib resulted in better patient-reported outcomes compared with chemotherapy among women with TNBC and BRCA mutations in the EMBRACA trial.
Want to read more?
Please login or register first to view this content.
